Quest Diagnostics (DGX) SVP sells and withholds shares under plan

Rhea-AI Filing Summary

Quest Diagnostics senior vice president Patrick Plewman reported two stock dispositions. He sold 410 shares of common stock in an open-market transaction at $207.73 per share under a Rule 10b5-1 sales plan he previously adopted.

He also disposed of 230 shares at $204.86 per share to cover tax obligations from the vesting of an earlier restricted share unit grant. After these transactions, he directly owns 15,198 shares of Quest Diagnostics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plewman Patrick

(Last) (First) (Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS INC

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP for Diagnostic Services

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		F		230(1)	D	$204.86	15,608	D
Common Stock	03/03/2026		S(2)		410	D	$207.73	15,198	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units.

2. This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

Remarks:

	Sean D. Mersten, Attorney in Fact for Patrick Plewman	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Quest Diagnostics (DGX) SVP Patrick Plewman report?

Patrick Plewman reported two dispositions of Quest Diagnostics common stock. One was an open-market sale of 410 shares, and the other was a 230-share disposition to satisfy tax obligations tied to restricted share unit vesting, both reflected in his updated direct ownership.

How many Quest Diagnostics (DGX) shares did the SVP sell and at what prices?

Patrick Plewman sold 410 Quest Diagnostics common shares at $207.73 each in an open-market transaction. He also disposed of 230 shares at $204.86 each to cover tax obligations from vesting restricted share units, as detailed in the Form 4 filing.

What is the purpose of the Quest Diagnostics (DGX) SVP’s 10b5-1 sales plan?

The open-market sale of 410 Quest Diagnostics shares was executed under a Rule 10b5-1 sales plan. Such plans allow insiders to pre-schedule trades, helping separate personal trading decisions from day-to-day access to nonpublic company information.

Why were some Quest Diagnostics (DGX) shares disposed of for tax withholding?

The 230-share disposition was used to satisfy tax obligations arising from the vesting of a prior restricted share unit grant. Instead of paying cash, shares are withheld or sold to cover taxes owed when equity awards convert into stock.

How many Quest Diagnostics (DGX) shares does the SVP own after these transactions?

After the reported transactions, Patrick Plewman directly owns 15,198 shares of Quest Diagnostics common stock. This updated ownership figure reflects both the 410-share open-market sale and the 230-share tax-withholding disposition disclosed in the Form 4.